Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Wednesday, 29'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously ap
Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline
11:02am, Wednesday, 29'th Jul 2026
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta names former Abbvie president as CEO as Ingram retires
09:19am, Monday, 27'th Jul 2026
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
08:30am, Monday, 27'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as c
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
10:26am, Wednesday, 22'nd Jul 2026
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
08:30am, Wednesday, 22'nd Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nas
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)
09:46am, Monday, 13'th Jul 2026
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against ce
2 Beaten-Down Stocks That Still Aren't Worth Buying
04:30pm, Saturday, 11'th Jul 2026
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
12:04pm, Friday, 10'th Jul 2026
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:25pm, Tuesday, 30'th Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously app
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
12:44pm, Tuesday, 30'th Jun 2026
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:SRPT) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
09:00am, Tuesday, 30'th Jun 2026
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administratio
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
08:30am, Tuesday, 30'th Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA
SRPT or PRTA: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 24'th Jun 2026
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value inv
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:48pm, Monday, 08'th Jun 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
